PTC Therapeutics Inc. (PTCT)
47.03
-3.93 (-7.71%)
At close: Apr 01, 2025, 3:02 PM
PTC Therapeutics Inc. Revenue Breakdown
| Quarter | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Jun 30, 2023 | Mar 31, 2023 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Manufacturing Revenue | 800K | 1.36M | 3.34M | 2.36M | 1.99M | 103.11M | 91.28M | 107.26M | 82.71M | 75.24M | 68.2M | 81.41M | 71.37M | 85.48M |
| Manufacturing Revenue Growth | -41.18% | -59.23% | +41.18% | +18.86% | -98.07% | +12.96% | -14.90% | +29.68% | +9.93% | +10.33% | -16.23% | +14.06% | -16.50% | n/a |
| Product Revenue | 135.42M | n/a | n/a | n/a | n/a | n/a | n/a | 4.09M | 696K | n/a | n/a | n/a | n/a | n/a |
| Product Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | +487.64% | n/a | n/a | n/a | n/a | n/a | n/a |
| Royalty Revenue | 61.37M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Royalty Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Quarter | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|
| Non-Us Revenue | 406.16M | 288.6M | 236M | 190.3M | 171.04M | 145.24M | 81.5M |
| Non-Us Revenue Growth | +40.73% | +22.29% | +24.01% | +11.26% | +17.77% | +78.21% | n/a |
| United States Revenue | 531.66M | 218.3M | 187.3M | n/a | n/a | n/a | n/a |
| United States Revenue Growth | +143.55% | +16.55% | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Quarter | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 73.46M | 69.5M | 73.27M | 76.29M | 80.89M | 88.45M | 86.91M | 92.72M | 80.12M | 79.89M | 73.27M | 86.55M | 69.25M | 68.88M | 61.09M | 75.46M | 57.84M | 53.66M | 58.21M | 63.5M | 49.28M | 49.22M | 40.54M | 48.67M | 38.37M | 33.55M | 32.97M | 35.48M | 31.42M | 28.87M | 25.5M | 24.17M | 23.65M | 23.37M | 25.94M | 25.89M | 21.37M | 17.21M | 17.61M |
| Selling, General, and Administrative Revenue Growth | +5.69% | -5.15% | -3.96% | -5.68% | -8.55% | +1.77% | -6.26% | +15.73% | +0.28% | +9.04% | -15.34% | +24.98% | +0.54% | +12.74% | -19.03% | +30.46% | +7.79% | -7.82% | -8.33% | +28.84% | +0.14% | +21.39% | -16.69% | +26.84% | +14.38% | +1.75% | -7.08% | +12.92% | +8.86% | +13.20% | +5.49% | +2.19% | +1.23% | -9.92% | +0.20% | +21.15% | +24.16% | -2.30% | n/a |
| Research and Development Revenue | 161.41M | 132.17M | 116.13M | 121.35M | 164.21M | 185.87M | 195.12M | 188.69M | 165.46M | 157.26M | 140.08M | 149.84M | 130.84M | 125.48M | 134.51M | 118.01M | 93M | 176.53M | 90.11M | 81.83M | 63.08M | 59.98M | 52.57M | 53.65M | 54.37M | 32.61M | 31.36M | 29.23M | 30.02M | 30.84M | 27.36M | 26.01M | 31.4M | 28.83M | 31.4M | 35.05M | 30.64M | 28.19M | 27.94M |
| Research and Development Revenue Growth | +22.13% | +13.81% | -4.30% | -26.10% | -11.65% | -4.74% | +3.41% | +14.04% | +5.21% | +12.27% | -6.52% | +14.52% | +4.27% | -6.71% | +13.98% | +26.90% | -47.32% | +95.91% | +10.11% | +29.73% | +5.16% | +14.10% | -2.02% | -1.33% | +66.74% | +3.97% | +7.28% | -2.63% | -2.63% | +12.69% | +5.20% | -17.15% | +8.91% | -8.19% | -10.41% | +14.39% | +8.69% | +0.90% | n/a |